1. 1) Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of Toll-like receptor signalling complexes. Nat. Rev. Immunol., 14, 546–558 (2014).
2. 2) Bayik D, Gursel I, Klinman DM. Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides. Pharmacol. Res., 105, 216–225 (2016).
3. 3) Klinman DM, Zeuner R, Yamada H, Gursel M, Currie D, Gursel I. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides. Ann. N. Y. Acad. Sci., 1002, 112–123 (2003).
4. 4) Yamada H, Gursel I, Takeshita F, Conover J, Ishii KJ, Gursel M, Takeshita S, Klinman DM. Effect of suppressive DNA on CpG-induced immune activation. J. Immunol., 169, 5590–5594 (2002).
5. 5) Lenert PS. Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm., 2010, 986596 (2010).